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Why was the cohort set up?
Greater life expectancy in Europe over the past few dec-
ades has been translated into an increasing burden of
chronic diseases that accumulate as the population ages,
whereas acute infectious diseases have been progressively
pushed into the background. The incidence of conditions
such as hypertension, obesity and asthma has increased
dramatically worldwide, and cancer, diabetes and respira-
tory and cardiovascular diseases are responsible for almost
70% of global deaths.1 Concurrently, the prevalence of
multimorbidity (as of people affected by more than one
chronic disorder) is also increasing and appears as the most
common chronic condition at present.2 Multimorbidity af-
fects almost 3 in 4 individuals aged 65 years and older,3
although it represents a problem not only for the elderly
but also for adult and even young populations,4 at whom
prevention strategies should aim.
People affected by multimorbidity often experience
fragmentation of care, greater and inadequate use of health
services5 and polypharmacy,6 which in turn may increase
the risk of low adherence and adverse drug reactions.7,8 All
of this leads to individuals’ quality of life deterioration9
and higher risk of mortality.10 Besides, handling patients
with multimorbidity represents a daily challenge for phys-
icians and health systems.11,12
Research on ageing and chronicity has been established
as a priority in the European health policy agenda,13 lead-
ing to the creation of the European Innovation Partnership
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on Active and Healthy Ageing (EIP on AHA) and the Joint
Actions on Chronic Diseases CHRODIS and CHRODISþ:
two initiatives of the European Commission in which mul-
timorbidity is tackled. However, many knowledge gaps on
the aetiology, epidemiology and risk factors of multimor-
bidity remain to be filled,14 which hinders the implementa-
tion of effective evidence-based interventions.
The European General Practice Research Network
(EGPRN) recently highlighted the importance of measur-
ing the impact of multimorbidity on health outcomes and
health service use, and prospective cohort studies were pro-
posed as the most appropriate study design15 since they en-
able study of multimorbidity over time in ‘real-life’
conditions.16 Population cohorts based on large clinical-
administrative databases have shown a high potential for
research in health and health services, and are among the
preferred options for this kind of investigation.17
In line with this, in 2005 the EpiChron Research Group
on Chronic Diseases began to study chronic diseases and
multimorbidity through data stored in the computerized
medical records of patients living in Aragon, a region of
north-eastern Spain. The relevance of the results obtained
with cross-sectional data encouraged the group to set up a re-
gional population cohort of 1.25 million inhabitants, named
the EpiChron Cohort Study, which was favourably evaluated
by the Clinical Research Ethics Committee of Aragon
(CEICA). Baseline data collection was finalized in December
2010 and follow-up is expected to extend until 2020. Both
cross-sectional and longitudinal studies on multimorbidity
and comorbidity of major index chronic diseases, as well as
pharmaco-epidemiological studies, are the main expected
outputs of this project. A longitudinal approach is essential
to identify causal relationships among risk factors, diseases
and drugs, development of chronic diseases and multimor-
bidity, and the incidence of adverse health outcomes.
Finally, data sharing and scaling-up of knowledge to dif-
ferent settings and/or countries are also key points of this pro-
ject. Cross-national comparisons may be useful to increase
the validity of results, and to identify social and structural
inequalities that may explain differences in the incidence and
evolution of chronic diseases and their impact on society.
One first step toward the integration and harmonization of
large health-related databases such as the EpiChron Cohort
was recently taken within the framework of the EIP on AHA,
with the final goal to create a structure capable of supporting
multi-country health care research projects.18
Who is in the cohort?
The EpiChron Cohort includes all inhabitants in the north-
eastern Spanish region of Aragon, registered as users of the
public health system (1 253 292 individuals on 1 January
2011, approximately 98% of the total number of inhabit-
ants in the region). It is a dynamic open cohort, so
that new users are continuously included throughout the
study period. All data contained in the cohort are
pseudonymized.
How often have they been followed up?
The follow-up of cohort participants is initially intended to
last for a period of 10 years, from 2011 to 2020, by means
of annual waves of data extraction on 1 January each year.
At present, six waves of data extraction have been con-
ducted, and information from 1 January 2011 to 31
December 2015 is available for research. The reasons for
early termination of follow-up are death of the individual
or withdrawal from the regional public health system. The
possibility of extending the follow-up period will be con-
sidered in 2020, according to the findings obtained during
the initial study period and available funding.
What has been measured?
The EpiChron Cohort links the information contained in
clinical-administrative databases from different care set-
tings at the individual level (e.g. patient index database,
primary, specialist, hospital and emergency care, and phar-
macy billing databases).
The variables collected in the cohort study can be classi-
fied as patient general data and demographic, clinical and
health outcomes, health care services use and pharmaceut-
ical data (Table 1). These variables derive from patients’
routine contacts with the regional health system, and sub-
sequently undergo depuration and quality control proc-
esses using computational algorithms. Raw data are also
subject to statistical treatment leading to the creation of
new variables related to specific research questions (e.g.
number of hospital readmissions in a given period of time,
number of visits to different care settings). The creation of
additional variables requires a clinical perspective and
research consensus (e.g. presence and type of multimorbid-
ity and/or polypharmacy, level of adherence to treatment,
immigrant status etc.). Moreover, original diagnoses are
re-coded according to the Expanded Diagnosis Clusters
(EDCs) using the Johns Hopkins ACGV
R
System19 which
groups together diseases that describe similar or related
conditions and is internationally used to define multimor-
bidity, together with the list of 114 chronic EDCs de-
veloped by Salisbury.11,20,21 Thus, the EpiChron Cohort is
not a mere integration of clinical-administrative databases,
but is also a population cohort specifically formed to serve
as a basis for research on the clinical epidemiology of
chronic diseases with a temporal horizon of 10 years. The
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most relevant baseline characteristics of the EpiChron
Cohort are summarized in Table 2. A ranking of the most
prevalent chronic conditions by sex and age is presented in
Table 3.
The integration of large numbers of multi-source data
enables information collection and analysis which would
be otherwise impossible, for example: (i) patients with a
specific index chronic condition; (ii) patterns of diseases
and their relation with health services use and negative
health outcomes such as mortality, adverse drug reactions,
hospital admissions for ambulatory care sensitive condi-
tions, and/or readmissions in a given period of time;
(iii) drug prescription profiles; and (iv) adherence to
medical plans. The study population will depend on
the aim of each study, ranging from the general population
to more specific groups of individuals such as older
adults, multimorbid patients or hospitalized patients.
We also study the epidemiology of chronic diseases and
multimorbidity in the immigrant population, defined
according to country of birth, nationality and length of
stay in the host country.22,23
The EpiChron Cohort has already been used to study
the comorbidity of major index chronic diseases such as
diabetes,24 chronic respiratory diseases (submitted manu-
script) and dementia,25 and studies on breast cancer and
heart failure are ongoing. The systematic association
among diseases (i.e. multimorbidity patterns) and among
drugs (i.e. polypharmacy patterns) has also been investi-
gated.26,27 Studies on the pharmaco-epidemiology of drugs
for chronic conditions such as agomelatine and cilostazol
have also been conducted28 focusing on the identification
of adverse drug reactions, lack of effectiveness and adher-
ence problems. The use of new oral antidiabetic drugs is
planned to be studied in the near future. The level of adher-
ence to pharmacological treatments for specific chronic
diseases and drug families has also been measured,29
Table 1. Original variables available in the EpiChron Cohort for each individual and in each data extraction wave according to
type of variable and data source
Type of variable Data source Variables measured
Sociodemographic data Patient Index Database Patient ID, sex, birthday, nationality/country of birth, registration date, city/
zip code, type of user, administrative health area, death or withdrawal
from the regional health service
Primary care Patient ID, centre ID, General practitioner ID
Specialist care Patient ID, centre ID, source of referral
Hospital care Patient ID, hospital ID, sex, birthday
Emergency room Patient ID, support date, duration of first evaluation, service
Pharmaceutical billing Patient ID
Patient General Data (DGP) Primary care Height, weight, drinking and smoking habits
Clinical and health outcomes data Primary care Diagnosesa (opening and closing date of the care episode), clinical parameters
(date and value), diagnostic tests (date and type of test), adverse drug reac-
tions (start and ending date, drug, route of administration, dose, adverse
reaction, hospital admission, outcome)
Hospital Diagnoses,b procedures, treatments, exitus (death), Diagnoses Related
Groups (DRG)
Emergency room Reason for visit, diagnoses,b diagnostic tests
Health care services use data Primary care Visits (date and type of visit, specialty), referrals (date of referral and
specialty)
Specialist care Date of visit, first/subsequent visit, medical specialty
Hospital care Date of admission, type of admission, date of discharge, reasons for dis-
charge, service of discharge, days in intensive care, length of stay, readmis-
sions, hospital transfer, surgical and diagnostic procedures
Emergency room Date of discharge, type of discharge
Pharmaceutical data Primary care ATCc code, dosage, number of packages, prescription date
Emergency room Number of prescriptions
Pharmaceutical billing Prescription date, billing date, ATCc code, national drug code, number of
packages, price, prescribing health care service
ID, identification.
aUsing the International Classification of Primary Care, 1st edition (ICPC).
bUsing the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).
cUsing the Anatomical, Therapeutic, Chemical (ATC) classification system.
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including cross-national comparisons that imply harmoni-
zation of the definition of adherence across contexts. We
have also measured the use of different health services by
specific population groups.22,24
All studies to date have been performed from a cross-
sectional point of view, offering a picture of the situation
at a given time point. These studies have been useful to de-
scribe and characterize the epidemiology of chronic dis-
eases and multimorbidity in the population and to
hypothesize potential causal associations among risk fac-
tors, diseases and health outcomes. The longitudinal ana-
lyses that we expect to carry out in the near future will
enable confirmation of cause-effect relationships or pre-
diction of trends over time. Specifically, we plan to con-
duct a number of studies aimed at describing trajectories of
multimorbidity over time and their relation with health
outcomes. The use of latent variable mixture modelling
(i.e. longitudinal latent class growth analysis and growth
mixture models) is one possible methodological approach
to identify distinctive developmental trajectories, calibrat-
ing the probability of single individuals following such
multimorbidity trajectories. Finally, predictive modelling
techniques will be performed to predict adverse health out-
comes in multimorbid patients, depending on demographic
variables and the incidence of specific chronic conditions
that might act as trigger for negative health outcomes,
reduced life expectancy and increased mortality.
What has it found? Key findings and
publications
A number of findings and publications have arisen from
the EpiChron Cohort Study, also before its official start in
2011. Multimorbidity was found to be strongly related to
the occurrence of adverse drug events, as far as it requires
the intervention of different specialists and the prescription
of multiple medications.30 The existence of non-random
associations among chronic diseases has been identified in
primary care patients, resulting in clinically meaningful
multimorbidity patterns26 (Table 4), some of which are
consistently described in the literature.31 Gender differ-
ences were detected in the prevalence of these patterns
among the population aged 65 years and older, probably
due to a higher life expectancy and/or worse health status
observed among women.32 Specific multimorbidity pat-
terns in hospitalized geriatric patients have also been
described, such as the induced-dependency and falls pat-
terns, which may facilitate the early detection of patients
with high vulnerability to stressors.33 Similarities for sev-
eral multimorbidity patterns were found in a cross-
national comparison with patients from The
Netherlands,34 which could offer initial clues for theT
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elaboration of clinical practice guidelines if further evi-
denced in other contexts.
We have further demonstrated the existence of non-
random associations among prescribed drugs, giving rise
to the so-called polypharmacy patterns27 (Table 4). These
patterns affect a significant proportion of the population
and are sound from both pharmacological and clinical
points of view, although future longitudinal studies are
needed to confirm some of the proposed causal
associations.
The nature and impact of comorbidities in patients with a
given chronic disease such as obesity, diabetes, dementia or
hypertension, has also been investigated. The coexistence of
mental comorbidity in patients with type 2 diabetes has been
Table 3. Baseline prevalence of most frequent chronic diseases by sex and age group in the EpiChron Cohort population in 2011
Age group Men Women
Disease (EDCa) Prevalence (%) Disease (EDC) Prevalence (%)
0–14 years Dermatitis and eczema 18.1 Dermatitis and eczema 19.4
Asthma 9.8 Asthma 6.7
Behaviour problems 6.5 Blindness 4.9
Blindness 4.1 Behaviour problems 4.0
Congenital anomalies of limbs, hands and feet 3.1 Congenital anomalies of limbs, hands, and feet 2.7
Developmental disorder 2.3 Kyphoscoliosis 2.0
Attention-deficit disorder 2.1 Other endocrine disorders 1.8
Kyphoscoliosis 1.5 Disease of hair and hair follicles 1.4
Obesity 1.3 Obesity 1.3
Deafness, hearing loss 1.2 Developmental disorder 1.3
15–44 years Disorders of lipid metabolism 6.5 Dermatitis and eczema 6.7
Dermatitis and eczema 5.0 Varicose veins of lower extremities 6.3
Asthma 3.7 Hypothyroidism 5.1
Obesity 2.8 Depression 5.1
Low back pain 2.8 Disease of hair and hair follicles 4.5
Depression 2.2 Asthma 4.4
Hypertension 2.2 Obesity 4.0
Disease of hair and hair follicles 1.8 Disorders of lipid metabolism 3.6
Substance use 1.7 Low back pain 3.5
Blindness 1.6 Anxiety, neuroses 3.3
45–64 years Disorders of lipid metabolism 27.1 Disorders of lipid metabolism 23.7
Hypertension 22.1 Hypertension 18.5
Diabetes 8.6 Varicose veins of lower extremities 16.1
Obesity 7.0 Depression 13.5
Arthropathy 6.0 Hypothyroidism 12.2
Dermatitis and eczema 6.0 Arthropathy 11.6
Depression 4.9 Osteoporosis 9.4
Low back pain 4.4 Obesity 9.2
Deafness, hearing loss 3.8 Dermatitis and eczema 7.3
Ischaemic heart disease (including AMIb) 3.7 Low back pain 5.2
 65 years Hypertension 52.8 Hypertension 59.1
Disorders of lipid metabolism 33.2 Disorders of lipid metabolism 37.3
Prostatic hypertrophy 20.9 Arthropathy 32.1
Diabetes 20.9 Varicose veins of lower extremities 25.2
Arthropathy 20.1 Osteoporosis 23.0
Cataract, aphakia 14.4 Depression 17.8
Emphysema, chronic bronchitis, COPD 12.7 Diabetes 17.2
Ischaemic heart disease (including AMI) 12.7 Cataract, aphakia 17.1
Cardiac arrhythmia 9.5 Obesity 13.4
Obesity 9.4 Hypothyroidism 12.7
COPD, chronic obstructive pulmonary disease; AMI, acute myocardial infarction.
aExpanded Diagnostic Clusters; only those considered as chronic by Salisbury et al.11 were taken into account.
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shown to increase the number of unplanned hospital admis-
sions, and discordant comorbidities have an important effect
on specialist care use.24 The two most frequent comorbidities
in patients with dementia were hypertension and diabetes, al-
though factor analysis showed that other comorbidities such
as Parkinson’s disease, congestive heart failure and cerebro-
vascular disease were significantly associated with the index
condition. These findings highlight that the analysis of
comorbidities for an index disease must not be exclusively
based on prevalence rates, but rather on methodologies that
allow for the discovery of non-random associations among
diseases.25 Mental comorbidities also affect the levels of ad-
herence to antihypertensive treatment in patients with hyper-
tension, underscoring the need for patient- rather than
disease-centred care.29
Regarding the pharmaco-epidemiology of drugs for
specific chronic conditions, a collaborative study con-
ducted in several European countries to characterize new
users of cilostazol, a drug to improve walking distances in
patients with intermittent claudication, showed that most
users were elderly patients with a high prevalence of
comorbidity, high concurrent use of interacting drugs and
high discontinuation rates in the first 3 months of
treatment.28
The effect of immigrant status on health and health ser-
vices use has also been investigated. The length of stay of
immigrants in the host country plays a decisive role on their
morbidity burden, observing a worsening of the health sta-
tus with longer stays in the host country.23 The global use
of health care services has been shown to be lower for im-
migrants than for nationals, which may be explained by the
healthy migrant effect or by possible inequalities in health
care provision.22 Immigrants’ pharmaceutical use has also
been studied and compared with that in a Norwegian set-
ting, and the similarities found between the two countries
highlights the need to consider specific immigrant-related
features when providing health care to this group of the
population.35
What are the main strengths and
weaknesses?
The main strength of the EpiChron Cohort lies in the fact
that it is a population cohort that represents almost the
Table 4. Prevalence of multimorbidity and polypharmacy patterns by age group and sex in the EpiChron Cohort. Adapted from
Prados-Torres et al., 201223 and Caldero´n-Larra~naga et al., 201324
Age Men Women
15–44 years Multimorbidity pattern Prevalence (%) Multimorbidity pattern Prevalence (%)
Cardiometabolic 0.9 Cardiometabolic 0.4
Psychiatric-substance abuse 1.5 Mechanical-obesity-thyroidal 3.7
Polypharmacy pattern Polypharmacy pattern
Depression-anxiety 0.8 Depression-anxiety 0.5
ARI 3.6 ARI 8.4
Rhinitis-asthma 0.1
45–64 years Multimorbidity pattern Multimorbidity pattern
Cardiometabolic 9.2 Cardiometabolic 4.1
Mechanical-obesity-thyroidal 4.9 Mechanical-obesity-thyroidal 16.6
Depressive 0.1
Polypharmacy pattern Polypharmacy pattern
Depression-anxiety 2.0 Depression-anxiety 11.9
CV 10.9 CV 3.6
COPD 5.2 ARI 7.4
Pain 4.5 Menopause 0.6
 65 years Multimorbidity pattern Multimorbidity pattern
Cardiometabolic 21.2 Cardiometabolic 33.3
Mechanical-obesity-thyroidal 13.6 Mechanical-obesity-thyroidal 3.5
Psychogeriatric 2.4 Psychogeriatric 17.3
Depressive 0.2
Polypharmacy pattern Polypharmacy pattern
Depression-anxiety 0.3 Depression-anxiety 37.5
CV 24.6 CV 8.9
COPD 25.3 COPD 7.4
ARI, acute respiratory infection; CV, cardiovascular; COPD, chronic obstructive pulmonary disease.
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entire population of Aragon (1.25 million individuals ap-
proximately), which is also representative of the Spanish
population in terms of age, sex and immigration. Data
are continuously subject to quality control procedures
that involve data collection, request, extraction and
processing to improve their reliability, validity, quality
and appropriateness for research. Specific data processing
carried out in the cohort is described in detail in Annex I,
available as Supplementary data at IJE online.
Furthermore, although the 10-year follow-up might not
be enough for studying the aetiology and prognosis of
some chronic diseases, it should be sufficient to study
mid- and long-term trends over time and to unravel
cause-effect relationships regarding multimorbidity and
specific chronic conditions.
Among the main weaknesses of the study, it is worth
highlighting that the cohort draws on information from
administrative databases and electronic health records
which have not been primarily designed for research pur-
poses, but for health care management. Consequently,
some errors or missingness may occur during registration
by health professionals, although they are continuously
trained in diagnosis coding and use of data collection soft-
ware. Some potential variables such as lifestyle factors are
not systematically gathered for all individuals, and others
such as socioeconomic and educational indicators are not
registered at all. However, socioeconomic status could be
indirectly known through the pharmaceutical co-payment
range established by the Spanish National Health System
according to legal order from 20 April 2012 (Official
State Gazette number 98 from 24 April 2012).
Furthermore, an effort is currently being made to link
other socioeconomic proxy variables (e.g. deprivation
index according to census section of participants). Finally,
data from private health care use are not included, al-
though they only represent less than 2% of the total health
care use in Aragon.
Can I get hold of the data? Where can I find
out more?
Data contained in the EpiChron Cohort are not expected
to be freely available on a public server for the moment.
However, requests for collaborative work regarding
complementary data analyses, cross-national compari-
sons or new methodological approaches to the study of
chronic diseases and multimorbidity are welcome. Data
sharing and integration of cohorts available in this area
are key points of the EpiChron Cohort Study. Please
contact the Principal Investigator (Alexandra Prados-
Torres) by e-mail [sprados.iacs@aragon.es] for further
information.
Supplementary Data
Supplementary data are available at IJE online.
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